Jansitin Duo (Metformin Hydrochloride, Sitagliptin)

Jansitin Duo combines metformin and sitagliptin to manage hyperglycaemia in type 2 diabetes.

• Type 2 diabetes mellitus: improves overall glycaemic control when diet and exercise are insufficient.
• Adjunct to insulin therapy: helps lower required insulin doses while maintaining target glucose levels.
• Combination with other oral antidiabetics: provides complementary mechanisms to further reduce blood glucose.

• Metformin decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity, while sitagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), leading to increased endogenous incretin (GLP‑1 and GIP) levels that boost glucose‑dependent insulin secretion and suppress glucagon release, together producing a synergistic reduction in blood glucose.

Jansitin Duo may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea.
• Headache: mild to moderate intensity.
• Mild hypoglycaemia: especially when used with sulfonylureas or insulin.

Serious or Rare Side Effects

• Lactic acidosis: a rare but life‑threatening metabolic complication.
• Severe hypoglycaemia: can occur with concomitant insulin or sulfonylureas.
• Pancreatitis: acute inflammation of the pancreas.
• Allergic reactions: rash, pruritus, or angio‑edema.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Renal impairment: worsening kidney function, particularly with metformin accumulation.

Before prescribing Jansitin Duo, clinicians should evaluate patient‑specific factors and monitor for potential risks.

• Renal function: assess baseline creatinine clearance and monitor periodically.
• Hepatic disease: use with caution in patients with liver impairment.
• Cardiovascular status: monitor for signs of heart failure, especially in elderly patients.
• Concomitant hypoglycaemic agents: adjust doses of sulfonylureas or insulin to avoid low blood sugar.
• Pregnancy and lactation: consider risk‑benefit ratio; consult current guidelines.
• Store at ambient temperature: keep in the original container, protect from moisture and heat.

Jansitin Duo can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

• Phenformin or other contraindicated biguanides: increased risk of lactic acidosis.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise sitagliptin plasma levels.
• Iodinated contrast agents: can impair renal function, heightening metformin‑related risks.

Moderate Interactions (Monitor Closely)

• Sulfonylureas: heightened risk of hypoglycaemia; dose adjustment may be needed.
• Insulin: may require reduction in insulin dose to prevent low glucose.
• Diuretics (especially thiazides): can affect metformin clearance and electrolyte balance.
• Cimetidine: may modestly increase sitagliptin exposure.
• Alcohol: excessive intake can potentiate metformin‑associated lactic acidosis.